Navigation Links
Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001
Date:11/2/2012

CARLSBAD, Calif., Nov. 2, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive a $1.25 million contingent payment from Pfizer Inc. (NYSE: PFE) triggered by Pfizer's decision to advance EXC 001 into a Phase 2 study.  In 2011, Isis received $4.4 million for its equity ownership of Excaliard from Pfizer's acquisition of Excaliard Pharmaceuticals and, excluding the $1.25 million, is eligible to receive an additional $8.35 million in contingent payments upon achievement of various milestones associated with the clinical and commercial progress of EXC 001, also referred to as PF-06473871.  Isis also remains eligible to receive milestone and royalty payments under its licensing agreement with Excaliard for EXC 001. 

"We have been extremely successful in implementing our business strategy to exploit our antisense drug discovery platform and create many opportunities outside of our core areas of therapeutic focus.  The development of EXC 001 is a great example of this success.  EXC 001 was co-discovered by Isis and Excaliard and developed to Phase 2 proof-of-principle by Excaliard.  Pfizer's commitment to advancing EXC 001 allows us to continue to benefit from our investment," said B. Lynne Parshall, J.D., chief operating officer and chief financial officer at Isis.  "The market opportunity to treat hypertrophic scars is very large, and Pfizer has the drug development expertise and global commercial infrastructure to support the continued advancement of EXC 001."

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. American Board of Radiology Foundation receives grant from Varian Medical Systems for national brachytherapy registry
2. Sihuans First-to-market Generic Drug Roxatidine Receives New Drug Certificate and Approval for Production
3. ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy
4. New York City Mayor Bloomberg and Health Commissioner Farley Receive Flu Shot at Duane Reade Pharmacy, Highlight Importance of Flu Preparedness
5. Par Pharmaceutical Receives Final Approval To Market Tretinoin Capsules
6. Intelomed Receives FDA 510(k) Clearance of CVInsight Medical Device
7. VirtualScopics Receives Issuance of Influential Patent in Canada
8. Lifeline Biotechnologies Receives Third Software Patent
9. Dehaier Medical Receives SFDA Approval for DHR-CPAP-C5
10. TechPrecision Receives Additional Medical Purchase Orders Exceeding $1.5 Million
11. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a ... extracellular matrix, today announced,that enrollment is complete in ... of superficial bladder cancer. The Company began dosing,patients ... following the successful,completion of the initial Phase I ...
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced that Schering-Plough has,initiated a Phase 1 ... a,compound identified from the collaboration between the two ... treatment for respiratory,disease. Pharmacopeia will receive a $1 ...
Cached Medicine Technology:Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 2Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 3Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 4Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 2Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 3Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 4
(Date:7/31/2015)... ... July 31, 2015 , ... ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... ... 31, 2015 , ... The Mount Sinai Health System will work with Columbia ... of related, experimental treatments. The collaboration moves into the next phase with the recent ... of five state licenses to produce and dispense medical marijuana. , Mount Sinai ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... penile enlargement techniques have also been advanced, upgraded, made more effective and less intrusive ... Loria of Loria Medical Penile Enlargement Center. Dr. Loria currently stands as the ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has ... angina until a heart rate of 150 beats versus 100 beats, this is a ... are able to give life back to patients with heart disease," he adds. People ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... who reported sleeping five hours or less per day when ... risk for substantial weight retention (11 pounds or more) at ... per day, according to a new study by Kaiser Permanente ... , The study, published in the November issue of ...
... Optimal Nutrition Inc. Chooses ,it, Girl PR to help promote ... ... 19 "it" Girl Public relations, one of,the leading Public ... addition of Optimal Nutrition Inc. (O.N.I.).,O.N.I. bestows a customized door-to-door ...
... Agency ... in Massachusetts -, WORCESTER, Mass., Nov. 19 The ... of auto, home and,business insurance in Massachusetts, announced today that ... auto product that will,deliver highly- competitive prices and innovative coverage ...
... Calif., Nov. 19 CorVel Corporation,(Nasdaq: CRVL ... shares,of its common stock under the stock repurchase ... In June 2006, the Board had approved a,1,500,000 ... 30,2007, the Company has repurchased 862,323 shares, with ...
... made, MINNEAPOLIS, Nov. 19 At its ... Directors of ClearWay Minnesota approved 11,grants for new ... Breathe Act,s,impact on young adults to interventions that ... Latino youth and African,immigrants. ClearWay Minnesota will award ...
... U.N. Environment Initiative to Northern New,Jersey, Planting ... MORRISTOWN, N.J., Nov. 18, 2007 Reaffirming,its ... Bayer,employee-volunteers and Girl Scouts from troops in ... grabbed their spades and planted 10,trees at ...
Cached Medicine News:Health News:Kaiser Permanente/Harvard Medical School study links lack of sleep to weight gain for new moms 2Health News:'it' Girl Public Relations Adds 'O.N.I.' New Organic Food Delivery Service to Its Lifestyle Division 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 3Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 4Health News:CorVel Corporation Announces Resumption of Stock Repurchases 2Health News:CorVel Corporation Announces Resumption of Stock Repurchases 3Health News:ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants 2Health News:ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants 3Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 2Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 3Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 4Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 5
... System RS 800 can sort different specimen ... sorting are not necessary anymore and all ... a very timesaving and economical way ... a Tube Type Identification via Cap Recognition ...
... detect sequences of the following viruses: ... and 3; influenza virus A and ... and B. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... for the detection of two genetic ... mutation on the Factor V (Leiden) ... the Prothrombin gene. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
Medicine Products: